Sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin for the treatment of high-risk, treatment-naive, non-muscle invasive bladder cancer.

被引：0
|
作者：
McElree, Ian M.
Steinberg, Ryan L.
Mott, Sarah L.
O'Donnell, Michael A.
Packiam, Vignesh T.
机构：
[1] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[2] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
[3] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
497
引用
收藏
页数：1
相关论文
共 50 条
  • [1] COMPARATIVE EFFECTIVENESS OF BACILLUS CALMETTE-GUERIN AND SEQUENTIAL INTRAVESICAL GEMCITABINE AND DOCETAXEL FOR TREATMENT-NAIVE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
    Ahmed, Eraky
    Kaushik, P. Kolanukuduru
    Reuben, Ben-David
    Mohammed, Almoflihi
    Sarah, Lidagoster
    Neeraja, Tillu
    Parissa, Alerasool
    Nikhil, Waigankar
    Kyrollis, Attalla
    Reza, Mehrazin
    Peter, Wiklund
    John, Sfakianos
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [2] Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
    McElree, Ian M.
    Steinberg, Ryan L.
    Mott, Sarah L.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JAMA NETWORK OPEN, 2023, 6 (02) : e230849
  • [3] Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guerin failure
    Shantharam, Govind
    Amin, Ali
    Pereira, Jorge
    Kott, Ohad
    Mueller-Leonhard, Catrina
    Mega, Anthony
    Golijanin, Dragan
    Gershman, Boris
    CURRENT UROLOGY, 2021, 15 (01) : 33 - 38
  • [4] INTRAVESICAL GEMCITABINE VERSUS INTRAVESICAL BACILLUS CALMETTE-GUERIN FOR THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER: AN EVALUATION OF EFFICACY AND TOLERANCE
    Prasanna, T.
    Kuo, J. C.
    Hickie, M.
    Sim, B. W. C.
    Pranavan, G.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 35 - 35
  • [5] Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
    Prasanna, Thiru
    Craft, Paul
    Balasingam, Gayathri
    Haxhimolla, Hodo
    Pranavan, Ganes
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [6] BACILLUS CALMETTE-GUERIN VERSUS SEQUENTIAL GEMCITABINE AND DOCETAXEL FOR TA HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
    Eraky, Ahmed
    Hug, Brenda
    Kolanukuduru, Kaushik P.
    Ben-David, Reuben
    Almoflihi, Mohammed
    Waigankar, Nikhil
    Attalla, Kyrollis
    Wiklund, Peter
    Mehrazin, Reza
    Sfakianos, John P.
    JOURNAL OF UROLOGY, 2025, 213 (5S):
  • [7] SEQUENTIAL INTRAVESICAL GEMCITABINE-DOCETAXEL VERSUS BACILLUS CALMETTE-GUERIN (BCG) IN THE TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER: A PRELIMINARY COST-EFFECTIVENESS ANALYSIS
    Bukavina, Laura
    Bell, Spencer
    Packiam, Vignesh
    Smaldone, Marc
    Abosh, Phillip
    Uzzo, Robert
    Kutikov, Alexander
    Correa, Andres
    Magee, Diana
    JOURNAL OF UROLOGY, 2023, 209 : E542 - E542
  • [8] Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer
    McElree, Ian M.
    Steinberg, Ryan L.
    Martin, Alex C.
    Richards, Jordan
    Mott, Sarah L.
    Gellhaus, Paul T.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JOURNAL OF UROLOGY, 2022, 208 (03): : 589 - 597
  • [9] Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer
    Sylvester, Richard J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2011, 18 (02) : 113 - 120
  • [10] EARLY CLINICAL EXPERIENCE WITH SEQUENTIAL INTRAVESICAL GEMCITABINE-DOCETAXEL FOR TREATMENT-NAIVE HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER
    Manuel, Refugia Justin
    Emily, Roebuck
    Parth, Thakker U.
    Ashok, Hemal
    Matvey, Tsivian
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S49 - S50
12345